US FTC probing DaVita, Fresenius Medical, Politico reports
Adds more details in paragraph 4, background in paragraph 6
July 13 (Reuters) -The U.S. Federal Trade Commission (FTC) is investigating healthcare providers DaVita DVA.N and Fresenius Medical Care FMEG.DE over allegations that the companies have been illegally thwarting smaller competitors, Politico reported on Saturday, citing three people familiar with the matter.
The investigation, which began earlier in the year and is in the early stages, focuses partly on how difficult the two companies that dominate the U.S. dialysis market have made it for physicians who work in their clinics to start new businesses or leave for their rivals, Politico said.
The FTC is examining the business model of the two companies, and is looking at whether non-compete agreements the companies make doctors sign hampers efforts by competitors who would want to make it easier for patients undergoing dialysis to be treated at home, according to Politico.
Politico said the non-compete agreements that are under investigation concern nephrologists, who specialize in treating Kidney disease.
The FTC, DaVita and Fresenius Medical did not immediately respond to a request for comment on the Politico report.
More than 500,000 people in the United States are on dialysis, a process of mechanically cleaning blood usually done three times a week. Diabetes is the most common cause of kidney failure.
Reporting by Chandni Shah in Bengaluru; Editing by Mark POtter and Diane Craft
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
